- McKesson maintains its forecast for the fiscal year’s adjusted earnings per share (EPS).
- The company anticipates adjusted EPS to range between $31.75 and $32.55.
- Analysts had estimated an adjusted EPS of $32.20.
- During the Wells Fargo Healthcare Conference, McKesson commented on their fiscal year guidance.
- For the second quarter of 2025, McKesson expects adjusted EPS between $6.70 and $7.00.
- On the day of the report, McKesson shares fell by 8.8%, closing at $521.10.
- A total of 89,989 McKesson shares were traded.
- Market sentiment included 16 buy ratings, 2 hold ratings, and 1 sell rating.
Mckesson Corp on Smartkarma
Analysts on Smartkarma, such as Baptista Research, are closely monitoring Mckesson Corp, providing valuable insights into its financial performance. In a recent report titled “McKesson Corporation: How Is The Revenue and Profit Growth Across Segments Expected To Evolve? – Major Drivers,” Baptista Research highlighted Mckesson Corporation’s strong Fourth Quarter Fiscal 2024 earnings. The company saw a 12% increase in consolidated revenue, reaching $309 billion, and a 6% rise in adjusted earnings per diluted share, surpassing initial expectations. Baptista Research acknowledges Mckesson’s success in achieving this growth across its enterprise, attributing it to the company’s diversified portfolio, innovative solutions, and dedication to quality and operational excellence.
A look at Mckesson Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 0 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 5 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts are optimistic about the long-term outlook for Mckesson Corp, with a strong focus on growth and resilience. The company has scored high on the Growth and Resilience factors in the Smartkarma Smart Scores, indicating its potential for future expansion and ability to weather challenges.
Momentum is also a significant factor for Mckesson Corp, although Value scored low. With a balanced score in Dividend, the company seems to be prioritizing reinvestment in growth opportunities. McKesson Corporation’s core business of distributing pharmaceuticals and healthcare products, along with its software development for the healthcare sector, positions it well for sustained growth and resilience in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
